| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.73(B) |
| Last
Volume: |
909,295 |
Avg
Vol: |
504,661 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,500 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$238,260 |
$238,260 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
25,597 |
29,385 |
30,235 |
146,471 |
| Total Sell Value |
$5,039,534 |
$5,596,862 |
$5,742,535 |
$29,817,809 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
4 |
5 |
6 |
17 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hunt Anthony |
Chief Executive Officer |
• • – |
2022-07-21 |
4 |
OE |
$32.40 |
$660,340 |
D/D |
20,154 |
219,469 |
|
- |
|
| Muir Glenn P |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
534 |
6,896 |
|
- |
|
| Konstantinov Konstantin |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
534 |
534 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
644 |
77,176 |
|
- |
|
| Eglinton Manner Carrie |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,024 |
1,481 |
|
- |
|
| Mhatre Rohin |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,202 |
1,659 |
|
- |
|
| Barthelemy Nicholas |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
534 |
2,081 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2022-05-25 |
4 |
AS |
$149.18 |
$2,214,819 |
D/D |
(14,715) |
76,532 |
|
43% |
|
| Gebski Christine |
See Remarks |
• – – |
2022-05-13 |
4 |
D |
$150.40 |
$50,384 |
D/D |
(335) |
34,092 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2022-05-13 |
4 |
D |
$150.40 |
$107,085 |
D/D |
(712) |
20,110 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2022-05-13 |
4 |
D |
$150.40 |
$107,085 |
D/D |
(712) |
39,187 |
|
- |
|
| Bylund James |
Chief Operating Officer |
• – – |
2022-04-01 |
4 |
D |
$188.02 |
$62,987 |
D/D |
(335) |
9,733 |
|
- |
|
| Eglinton Manner Carrie |
Director |
– • – |
2022-03-16 |
4 |
B |
$175.02 |
$109,388 |
D/D |
625 |
2,106 |
2.39 |
13% |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2022-03-08 |
4 |
OE |
$33.87 |
$172,242 |
D/D |
4,166 |
39,899 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2022-03-01 |
4 |
D |
$194.06 |
$1,415,086 |
D/D |
(7,292) |
199,315 |
|
- |
|
| Ryan Thomas F Jr |
Director |
– • – |
2022-03-01 |
4 |
S |
$197.58 |
$396,060 |
D/D |
(2,000) |
1,457 |
|
11% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2022-03-01 |
4 |
OE |
$38.76 |
$38,760 |
D/D |
1,000 |
3,457 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2022-02-28 |
4 |
D |
$196.70 |
$117,627 |
D/D |
(598) |
34,427 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2022-02-28 |
4 |
D |
$196.70 |
$404,612 |
D/D |
(2,057) |
20,822 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,234 |
22,406 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2022-02-28 |
4 |
D |
$196.70 |
$615,474 |
D/D |
(3,129) |
35,733 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,922 |
38,201 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2022-02-28 |
4 |
D |
$196.70 |
$3,253,025 |
D/D |
(16,538) |
206,607 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
30,074 |
219,975 |
|
- |
|
| Gebski Christine |
See Remarks |
• – – |
2022-02-27 |
4 |
D |
$196.70 |
$90,875 |
D/D |
(462) |
35,025 |
|
- |
|
464 Records found
|
|
Page 5 of 19 |
|
|
5.84 (3.56%) 
